Arca
Skip to content
Tools
Tools

Vascular endothelial growth factor receptor

Family in Homo sapiens that 40 drugs act on.

  • Drugs that act on it: 40
  • Approved: 10
  • In phases 1 to 3: 30
  • Sponsors: 25
  • Genes: 3

Who is on it, and how far along

Every drug ChEMBL records acting on FLT1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 37
  • Other 3

Approved10

Phase 310

Phase 211

Phase 19

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Vascular endothelial growth factor receptor inhibitor.
LenvatinibApprovedEisaiSmall moleculeInhibitor329
FruquintinibApprovedTakeda Pharmaceuticals USASmall moleculeInhibitor110
RegorafenibBoxed warningApprovedBayerSmall moleculeInhibitor96
SorafenibApprovedBayerSmall moleculeInhibitor62
AxitinibApprovedPfizerSmall moleculeInhibitor56
SunitinibBoxed warningApprovedCPPI CVSmall moleculeInhibitor54
PazopanibBoxed warningApprovedNovartis PharmaceuticalsSmall moleculeInhibitor27
NintedanibApprovedCSPC Pharmaceutical GroupSmall moleculeInhibitor26
TivozanibApprovedLG ChemSmall moleculeInhibitor8
VandetanibBoxed warningApprovedSanofiSmall moleculeInhibitor3
SurufatinibPhase 3Hutchison Medipharma LimitedSmall moleculeInhibitor42
CediranibPhase 3AstraZeneca PharmaceuticalsSmall moleculeInhibitor18
MotesanibPhase 3GERONSmall moleculeInhibitor8
BrivanibPhase 3Bristol-Myers SquibbSmall moleculeInhibitor0
Brivanib alaninatePhase 3Bristol-Myers SquibbSmall moleculeInhibitor0
DovitinibPhase 3Novartis PharmaceuticalsSmall moleculeInhibitor0
IbcasertibPhase 3Chipscreen Biosciences, Ltd.Small moleculeInhibitor0
LinifanibPhase 3AbbVieSmall moleculeInhibitor0
SemaxanibPhase 3—Small moleculeInhibitor0
VatalanibPhase 3Novartis PharmaceuticalsSmall moleculeInhibitor0
CEP-11981Phase 2Teva Pharmaceutical IndustriesSmall moleculeInhibitor1
AG-13958Phase 2—Small moleculeInhibitor0
BMS-690514Phase 2Bristol-Myers SquibbSmall moleculeInhibitor0
ForetinibPhase 2GSKSmall moleculeInhibitor0
GlesatinibPhase 2Mirati TherapeuticsSmall moleculeInhibitor0
IlorasertibPhase 2AbbVieSmall moleculeInhibitor0
LucitanibPhase 2Clovis Oncology, Inc.Small moleculeInhibitor0
SU-014813Phase 2PfizerSmall moleculeInhibitor0
X-82Phase 2TyrogenexOtherInhibitor0
XL-820Phase 2ExelixisOtherInhibitor0
XL-999Phase 2Symphony Evolution, Inc.Small moleculeInhibitor0
4SC-203Phase 14SC AGSmall moleculeInhibitor0
CEP-5214Phase 1—Small moleculeInhibitor0
CEP-7055Phase 1—Small moleculeInhibitor0
CP-459632Phase 1—OtherInhibitor0
KRN-633Phase 1—Small moleculeInhibitor0
L-21649Phase 1—Small moleculeInhibitor0
OSI-930Phase 1Astellas PharmaSmall moleculeInhibitor0
RG-1530Phase 1RocheSmall moleculeInhibitor0
TAK-593Phase 1Takeda Pharmaceuticals USASmall moleculeInhibitor0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 96 in all, from ClinicalTrials.gov.
Chemotherapy-Minimized Blank Microsphere Transarterial Embolization (BMS-TACE) Plus Low-Dose Lenvatinib, Iparomlimab and Tuvonralimab, and SBRT in Hepatocellular Carcinoma With Macrovascular Tumor ThrombusLenvatinibPhase 2RecruitingSun Yat-sen UniversityNov 20, 2026
Yangyin Qingfei Decoction for Radiation Pneumonitis PreventionNintedanibPhase 2Not yet recruitingThe First Affiliated Hospital of Zhejiang Chinese Medical UniversityNov 17, 2026
Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma.LenvatinibPhase 2RecruitingKidney Cancer Research BureauNov 16, 2026
A Single-Arm, Exploratory, Phase II Study of Iparomlimab and Tuvonralimab Combined With Local Therapy as First-Line Treatment for Hepatocellular Carcinoma With Portal Vein Tumor ThrombusLenvatinibPhase 2Not yet recruitingFujian Cancer HospitalNov 16, 2026
A Trial Evaluating Two Imetelstat Doses in Participants With Lower Risk Myelodysplastic Syndrome (MDS)MotesanibPhase 4Not yet recruitingGeron CorporationNov 16, 2026
Efficacy and Safety Exploration of Short Course Radiotherapy Followed by Surufatinib and Toripalimab in Neoadjuvant Treatment of Locally Advanced Rectal CancerSurufatinibPhase 2 / Phase 3RecruitingThe First Hospital of Jilin UniversityNov 13, 2026
Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid TumorsLenvatinibPhase 1 / Phase 2Not yet recruitingQilu Pharmaceutical Co., Ltd.Nov 12, 2026
QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma PatientsLenvatinibPhase 2Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNov 12, 2026
A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary FibrosisNintedanibPhase 2Not yet recruitingCSPC-NBP Pharmaceutical Co., Ltd.Nov 12, 2026
Predictive Factors of Long-term Survivor (LTS) of Patients With Recurrent or Metastatic, Radio-iodine Resistant Differentiated Thyroid Cancer (RRDTC) After Lenvatinib: a Multicenter StudyLenvatinib—Not yet recruitingIRCCS San RaffaeleNov 10, 2026
Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer PatientsLenvatinibPhase 2RecruitingKidney Cancer Research BureauNov 10, 2026
Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell CarcinomaLenvatinibPhase 2Not yet recruitingSun Yat-sen UniversityNov 6, 2026
Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction AdenocarcinomaFruquintinibPhase 2RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNov 5, 2026
GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal CancerFruquintinibPhase 3Not yet recruitingGenfleet Therapeutics (Shanghai) Inc.Nov 3, 2026
Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver MetastasesSunitinib—Enrolling by invitationChiyi ChenNov 3, 2026
Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCTMotesanibPhase 1Not yet recruitingUniversity of Wisconsin, MadisonNov 2, 2026
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib for Advanced Colorectal CancerFruquintinibPhase 2Not yet recruitingWest China HospitalOct 29, 2026
A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell CarcinomaFruquintinibPhase 3Not yet recruitingSun Yat-sen UniversityOct 29, 2026
Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later TreatmentFruquintinibPhase 2RecruitingRenmin Hospital of Wuhan UniversityOct 26, 2026
SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal CancerFruquintinibPhase 2RecruitingRuijin HospitalOct 22, 2026
Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy in Patients With Liver-Only Metastatic Colorectal CancerFruquintinibPhase 3Not yet recruitingWest China HospitalOct 21, 2026
Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell CarcinomaSunitinibPhase 3Active, not recruitingSun Yat-sen UniversityOct 20, 2026
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid TumorsRegorafenibPhase 1 / Phase 2Not yet recruitingCSPC Megalith Biopharmaceutical Co.,Ltd.Oct 5, 2026
First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in SpainAxitinib, Pazopanib, Sunitinib, Tivozanib—Active, not recruitingBristol-Myers SquibbOct 1, 2026
Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular CarcinomaSorafenibPhase 3RecruitingBeOne MedicinesSep 23, 2026
Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPCSurufatinibPhase 2Not yet recruitingShanghai Zhongshan HospitalSep 22, 2026
MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary CarcinomasAxitinibPhase 2Not yet recruitingFudan UniversitySep 14, 2026
A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric CancerFruquintinibPhase 2Not yet recruitingCancer Hospital Chinese Academy of Medical Science, Shenzhen CenterSep 14, 2026
Real-world Insight Into Systemic Therapies for HCC: Single-center StudySorafenib—RecruitingMansoura UniversitySep 10, 2026
Molecularly Tailored Therapy in Advanced Pancreatic CancerAxitinibPhase 2Not yet recruitingHerlev HospitalSep 3, 2026
Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk OsteosarcomaSorafenibPhase 2RecruitingAnna RaciborskaAug 26, 2026
Real-World Study of the Safety and Efficacy of Surufatinib in the Treatment of Neuroendocrine TumorsSurufatinib—Not yet recruitingYefengAug 21, 2026
TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell CarcinomaAxitinibPhase 2Not yet recruitingFudan UniversityAug 20, 2026
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerRegorafenibPhase 2Not yet recruitingFujian Cancer HospitalAug 14, 2026
A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal CancerRegorafenibPhase 1 / Phase 2Not yet recruitingCSPC Megalith Biopharmaceutical Co.,Ltd.Aug 6, 2026
SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell CarcinomaAxitinibPhase 2RecruitingHebei Medical University Fourth HospitalAug 4, 2026
A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and IrinotecanRegorafenibPhase 3Not yet recruitingSichuan Baili Pharmaceutical Co., Ltd.Jul 28, 2026
IBI363 Combined With Bevacizumab for Advanced Colorectal CancerRegorafenibPhase 3RecruitingInnovent Biologics (Suzhou) Co. Ltd.Jul 23, 2026
Antifibrotic Therapy Decision-Making in Pulmonary FibrosisNintedanib—Not yet recruitingBristol-Myers SquibbJul 23, 2026
DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AMLSorafenibPhase 3RecruitingThe Second Affiliated Hospital of Kunming Medical UniversityJul 20, 2026
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat SyndromeRegorafenibPhase 2Not yet recruitingXiang-QianJul 9, 2026
A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and PimitespibRegorafenib, SunitinibPhase 2RecruitingGlaxoSmithKlineJul 8, 2026
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary FibrosisNintedanibPhase 2RecruitingMannkind CorporationJul 1, 2026
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian CancerSunitinibPhase 2RecruitingBai-Rong XiaJun 25, 2026
A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold RegionsSorafenib—Active, not recruitingHarbin Medical UniversityJun 12, 2026
PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCCAxitinibPhase 1 / Phase 2Not yet recruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesJun 5, 2026
A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary HypertensionNintedanib—Not yet recruitingCosmos Rx, IncMay 29, 2026
Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLCSurufatinibPhase 2RecruitingSun Yat-sen UniversityMay 27, 2026
Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular DegenerationAxitinibPhase 2Not yet recruitingSCAI TherapeuticsMay 26, 2026
Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)NintedanibPhase 2Not yet recruitingFirst Affiliated Hospital of Wenzhou Medical UniversityMay 13, 2026
Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AMLSorafenib—Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyMay 7, 2026
Clinical Study of Novel Therapeutic Vaccine for Advanced Solid TumorsRegorafenibPhase 1RecruitingWest China HospitalMay 5, 2026
SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical IndomethacinSorafenibPhase 2RecruitingNational Taiwan University HospitalMay 1, 2026
Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative NeoplasmsMotesanibPhase 2Not yet recruitingM.D. Anderson Cancer CenterApr 24, 2026
Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort StudySurufatinib—Active, not recruitingWest China HospitalApr 16, 2026
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary FibrosisNintedanibPhase 3Not yet recruitingHaisco Pharmaceutical Group Co., Ltd.Apr 9, 2026
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 StudyAxitinibPhase 3RecruitingOcular Therapeutix, Inc.Apr 7, 2026
Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk CriteriaSurufatinibPhase 2 / Phase 3RecruitingThe First Hospital of Jilin UniversityApr 1, 2026
Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILDNintedanib—RecruitingUniversity of PatrasMar 24, 2026
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaSunitinibPhase 2RecruitingMemorial Sloan Kettering Cancer CenterMar 17, 2026
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic CancerSurufatinibPhase 2Not yet recruitingSun Yat-sen UniversityMar 13, 2026
MRD-guided Maintenance Post-HCT: Gilteritini vs SorafenibSorafenibPhase 3RecruitingThe First Affiliated Hospital of Soochow UniversityMar 11, 2026
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasPazopanibPhase 1RecruitingM.D. Anderson Cancer CenterMar 3, 2026
Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic CancerSurufatinibPhase 3RecruitingTianjin Medical University Cancer Institute and HospitalFeb 27, 2026
Imetelstat Combinations in Relapsed AMLMotesanibPhase 1RecruitingDouglas TremblayJan 6, 2026
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapySunitinibPhase 3RecruitingGlaxoSmithKlineOct 21, 2025
A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKISunitinibPhase 3Not yet recruitingPeking University Cancer Hospital & InstituteSep 10, 2025
A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell CarcinomaPazopanibPhase 2RecruitingImbioray (Hangzhou) Biomedicine Co., Ltd.Jul 25, 2025
Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)PazopanibPhase 1 / Phase 2RecruitingTianjin Medical University Second HospitalMar 26, 2025
Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or AdolescentsPazopanibPhase 2RecruitingShandong Cancer Hospital and InstituteFeb 10, 2025
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionPazopanibPhase 2RecruitingTianjin Medical University Second HospitalDec 18, 2024
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)PazopanibPhase 3RecruitingSun Yat-sen UniversityDec 10, 2024
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney CancerTivozanibPhase 3RecruitingAlliance for Clinical Trials in OncologyOct 28, 2024
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerVandetanibPhase 2RecruitingWest China HospitalJul 1, 2024
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)PazopanibPhase 3RecruitingIntensity Therapeutics, Inc.Feb 16, 2024
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyMotesanibPhase 1RecruitingChildren's Oncology GroupFeb 8, 2024
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaTivozanibPhase 2Active, not recruitingM.D. Anderson Cancer CenterSep 26, 2023
Multicenter Trial of ESK981 in Patients With Select Solid TumorsCEP-11981Phase 2Active, not recruitingUniversity of Michigan Rogel Cancer CenterAug 14, 2023
Drug Screening Using Novel IMD in Renal Cell CarcinomaTivozanibPhase 1RecruitingOliver JonasJan 26, 2023
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsTivozanibPhase 1RecruitingArcus Biosciences, Inc.Sep 10, 2022
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With MyelofibrosisMotesanibPhase 1Active, not recruitingGeron CorporationMay 12, 2022
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesTivozanibPhase 1 / Phase 2RecruitingUniversity of FloridaAug 11, 2021
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsCediranibPhase 2Active, not recruitingNational Cancer Institute (NCI)Feb 5, 2021
TDM for Optimized Outcome in Patients With mRCC.Tivozanib—RecruitingNiels FristrupDec 9, 2020
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract CancersTivozanibPhase 1 / Phase 2RecruitingNational Cancer Institute (NCI)Nov 27, 2020
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentMotesanibPhase 3Active, not recruitingGeron CorporationOct 6, 2020
A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical CancerCediranibPhase 2Active, not recruitingThe Clatterbridge Cancer Centre NHS Foundation TrustJul 27, 2020
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid CancerVandetanibPhase 3Active, not recruitingLoxo Oncology, Inc.Dec 26, 2019
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerCediranibPhase 2RecruitingM.D. Anderson Cancer CenterSep 16, 2019
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid TumorsCediranibPhase 2Active, not recruitingUniversity Health Network, TorontoFeb 22, 2019
WIRE - Novel Treatments in Renal Cell CancerCediranibPhase 2RecruitingCCTU- Cancer ThemeNov 14, 2018
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneCediranibPhase 2Active, not recruitingNational Cancer Institute (NCI)Sep 7, 2018
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyCediranibPhase 2Active, not recruitingAstraZenecaNov 7, 2017
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent GlioblastomaCediranibPhase 2Active, not recruitingNational Cancer Institute (NCI)Nov 28, 2016
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)MotesanibPhase 2 / Phase 3Active, not recruitingGeron CorporationNov 6, 2015
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerVandetanibPhase 2Active, not recruitingUNICANCERNov 24, 2014

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2095227, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.